Amylyx Pharmaceuticals Statistics
Share Statistics
Amylyx Pharmaceuticals has 89.08M
shares outstanding. The number of shares has increased by 30.29%
in one year.
| Shares Outstanding | 89.08M |
| Shares Change (YoY) | 30.29% |
| Shares Change (QoQ) | 29.26% |
| Owned by Institutions (%) | 73.12% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,672 |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 4.2M, so 4.71% of the outstanding
shares have been sold short.
| Short Interest | 4.2M |
| Short % of Shares Out | 4.71% |
| Short % of Float | 5.2% |
| Short Ratio (days to cover) | 5.09 |
Valuation Ratios
The PE ratio is -0.85 and the forward
PE ratio is -2.46.
Amylyx Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -0.85 |
| Forward PE | -2.46 |
| PS Ratio | 2.95 |
| Forward PS | 2.9 |
| PB Ratio | 1.56 |
| P/FCF Ratio | -1.53 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Amylyx Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.67,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.67 |
| Quick Ratio | 6.67 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $710,333.33 |
| Profits Per Employee | $-2,453,195.12 |
| Employee Count | 123 |
| Asset Turnover | 0.45 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -393K |
| Effective Tax Rate | 0.13% |
Stock Price Statistics
The stock price has increased by 163.07% in the
last 52 weeks. The beta is -0.59, so Amylyx Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -0.59 |
| 52-Week Price Change | 163.07% |
| 50-Day Moving Average | 4.01 |
| 200-Day Moving Average | 3.74 |
| Relative Strength Index (RSI) | 52.13 |
| Average Volume (20 Days) | 825,190 |
Income Statement
In the last 12 months, Amylyx Pharmaceuticals had revenue of 87.37M
and earned -301.74M
in profits. Earnings per share was -4.43.
| Revenue | 87.37M |
| Gross Profit | 45.22M |
| Operating Income | -314.73M |
| Net Income | -301.74M |
| EBITDA | -301.23M |
| EBIT | -291.88M |
| Earnings Per Share (EPS) | -4.43 |
Full Income StatementBalance Sheet
The company has 77.39M in cash and 1.98M in
debt, giving a net cash position of 75.41M.
| Cash & Cash Equivalents | 77.39M |
| Total Debt | 1.98M |
| Net Cash | 75.41M |
| Retained Earnings | -606.69M |
| Total Assets | 193.63M |
| Working Capital | 161.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -167.65M
and capital expenditures -157K, giving a free cash flow of -167.8M.
| Operating Cash Flow | -167.65M |
| Capital Expenditures | -157K |
| Free Cash Flow | -167.8M |
| FCF Per Share | -2.46 |
Full Cash Flow StatementMargins
Gross margin is 51.75%, with operating and profit margins of -360.22% and -345.36%.
| Gross Margin | 51.75% |
| Operating Margin | -360.22% |
| Pretax Margin | -345.81% |
| Profit Margin | -345.36% |
| EBITDA Margin | -344.77% |
| EBIT Margin | -360.22% |
| FCF Margin | -192.06% |
